A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs SPR-206 (Primary)
- Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 07 Jan 2019 According to a Spero Therapeutics media release, top-line data from the study is expected in the second half of 2019.
- 31 Dec 2018 Status changed from planning to recruiting.
- 08 Nov 2018 According to a Spero Therapeutics media release, the company is planning to start this study around year-end 2018 .